上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。
3M-011
3M-011 是一种有效的双重 TLR7/8 激动剂和一种细胞因子诱导剂。3M-011 显着抑制 H3N2 流感病毒在鼻腔中的复制。3M-011 还是一种放疗的有效佐剂，可在放疗过程中诱导局部和深远的全身免疫反应。3M-011 具有强大的抗肿瘤作用。
3M-011 Chemical Structure
CAS No. : 642473-62-9
| 规格 |
|
是否有货 |
|
| 100 mg |
|
询价 |
|
| 250 mg |
|
询价 |
|
| 500 mg |
|
询价 |
|
* Please select Quantity before adding items.
| 生物活性 |
3M-011 is a potent dual toll-like receptor TLR7/8 agonist and a cytokine inducer. 3M-011 significantly inhibits H3N2 influenza viral replication in the nasal cavity. 3M-011 is also a potent adjuvant to radiotherapy that induces local and profound systemic immune responses during radiotherapy. 3M-011 strongly has antitumor action[1][2][3].
|
| IC50 & Target[1][2] |
|
TLR7
|
TLR8
|
H3N2 influenza viral
|
|
体外研究
(In Vitro) |
3M-011 (0-100 μg/mL; 24 hours; B16-F10 melanoma cells) treatment can decrease B16-F10 melanoma cell counts[1].
3M-011 potentiates natural killer (NK) cells cytotoxicity[1].
The NF-κB reporter is stably integrated into HEK-293 cells that are subsequently transiently transfected with human or mouse TLR7 or TLR8. With all the TLRs tested, except mouse TLR8, stimulation with 3M-011 results in a dose-dependent induction of NF-κB-controlled luciferase activity. 3M-011 in humans activates both TLR7 and TLR8, whereas in mice, 3M011 activates only TLR7 and not TLR8[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cytotoxicity Assay[1]
| Cell Line: |
B16-F10 melanoma cells |
| Concentration: |
0 μg/mL, 1 μg/mL, 10 μg/mL, 33 μg/mL, 67 μg/mL, 100 μg/mL |
| Incubation Time: |
24 hours |
| Result: |
Decreased B16-F10 melanoma cell counts. |
|
体内研究
(In Vivo) |
3M-011 (1 mg/kg; intravenous injection; every other day with six doses; female scid/NOD mice) treatment shows antitumor effects in scid/NOD mice bearing B16-F10 cells[1].
Wild-type C57BL/6 mice are injected subcutaneously with different doses of 3M-011 (0.01 mg/kg, 0.1 mg/kg, 1 mg/kg, or 10 mg/kg). 3M-011 induces a dose-dependent increase in serum concentrations of both TNF-α and IFN-α/β[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: |
Female scid/NOD mice (8-12-week-old) injected with B16-F10 cells[1] |
| Dosage: |
1 mg/kg |
| Administration: |
Intravenous injection; every other day with six doses |
| Result: |
Had antitumor effects in scid/NOD mice bearing B16-F10 cells. |
|
| 分子量 |
|
| Formula |
|
| CAS 号 |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| 参考文献 |
-
[1]. Dumitru CD, et al. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model. Cancer Immunol Immunother. 2009 Apr;58(4):575-87.
[2]. Hammerbeck DM, et al. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res. 2007 Jan;73(1):1-11.
[3]. Schölch S, et al. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget. 2015 Mar 10;6(7):4663-76.
|
所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务
